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Background and purpose Propionyl-l-carnitine (pLc) exerts protective effects in different 
experimental models of ischemia–reperfusion (I/R).  The aim of the present study was to assess 
the effects of intravenously and topically applied pLc on microvascular permeability increase 
induced by I/R in the hamster cheek pouch preparation. Methods The hamster cheek pouch 
microcirculation was visualized by fluorescence microscopy. Microvascular permeability, 
leukocyte adhesion to venular walls, perfused capillary length, and capillary red blood cell 
velocity (VRBC) were evaluated by computer-assisted methods. E-selectin expression was 
assessed by in vitro analysis. Lipid peroxidation and reactive oxygen species (ROS) formation 
were determined by thiobarbituric acid-reactive substances (TBARS) and 2′-7′-dichlorofluorescein 
(DCF), respectively. Results In control animals, I/R caused a significant increase in permeability 
and in the leukocyte adhesion in venules. Capillary perfusion and VRBC decreased.  TBARS levels 
and DCF fluorescence significantly increased compared with baseline. Intravenously infused pLc 
dose-dependently prevented leakage and leukocyte adhesion, preserved capillary perfusion, and 
induced vasodilation at the end of reperfusion, while ROS concentration decreased. Inhibition of 
nitric oxide synthase prior to pLc caused vasoconstriction and partially blunted the pLc-induced 
protective effects; inhibition of the endothelium-derived hyperpolarizing factor (EDHF) abolished 
pLc effects.  Topical application of pLc on cheek pouch membrane produced the same effects as 
observed with intravenous administration. pLc decreased the E-selectin expression. Conclusions 
pLc prevents microvascular changes induced by I/R injury.  The reduction of permeability increase 
could be mainly due to EDHF release induce vasodilatation together with NO. The reduction of 
E-selectin expression prevents leukocyte adhesion and permeability increase.
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1991). Recent studies demonstrated that the pLc administration 
to human patients suffering from chronic ischemic heart disease 
improves the left ventricular function, decreases systemic and pul-
monary resistance, and enhances cardiac efficiency (Chiddo et al., 
1991). Tarantini et al. (2006) showed that pLc reduces early mortality 
of patients with anterior acute myocardial infarction.
pLc exhibits hemodynamic effects, improving peripheral vascu-
lar blood flow in patients with peripheral artery obstructive disease 
(PAOD), reducing the plasma levels of adhesion molecules (E, L, 
and P-selectin, ICAM-1 and VCAM-1) that are known to increase 
damage in ischemic tissues (Signorelli et al., 2001; Silvestro et al., 
2006; Loffredo et al., 2007).
Several studies have been carried out to clarify the mechanism 
by which pLc prevents the I/R injuries. It has been reported that 
pLc increases NO availability in isolated small mesenteric arteries 
from spontaneously hypertensive rats (Alvarez de Sotomayor et al., 
2007). This effect has been confirmed in experiments carried out 
in rat livers subjected to warm I/R showing an increase in hepatic 
blood flow, measured by laser Doppler technique, after pLc treat-
ment (Yonezawa et al., 2005).
IntroductIon
l-Carnitine has been proven to induce beneficial effects on ischemic 
tissues, including myocardium and skeletal muscle. One of the most 
utilized derivates of l-carnitine is propionyl-l-carnitine (pLc), a 
naturally  short-chain  fatty  ester  of  carnitine  (3-hydroxy-4-N-
  trimethyl-aminobutyric acid). pLc increases the intracellular pool 
of L-carnitine that has a crucial function in the transport of long-
chain fatty acids into mitochondria for oxidation, particularly in 
the heart and skeletal muscles. It is able to chaperon activated fatty 
acids into mitochondrial matrix for metabolism and prevents accu-
mulation of intermediate compounds in the mitochondrial matrix 
to facilitate energy production (Wiseman and Brogden, 1988).
Several previous studies indicate that administration of pLc 
ameliorates damage due to ischemia and subsequent reperfusion 
in different organs (Shug et al., 1991; Mister et al., 2002).
Two studies carried out on rabbit and rat isolated hearts, subjected 
to ischemia and reperfusion (I/R), demonstrated that pLc improves 
the functional recovery of the myocardium. Such protective effects 
are proposed mediated by a reduction in oxidative stress due to 
oxygen-derived free radicals (ROS) (Ferrari et al., 1989; Packer et al., Frontiers in Physiology  |  Vascular Physiology    October 2010  | Volume 1  | Article 132  |  2
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  beginning of reperfusion, with a time interval of 10 min after each 
drug administration, as previously described. (7) The seventh 
group of animals (P5, n = 40) was treated with topical l-NAME 
(1 mM) plus Apamin (0.3 μM) and Charybdotoxin (0.1 μM) prior 
to pLc (2.5 mM), starting 30 min before ischemia and at the 
beginning of reperfusion, with a time interval of 8 min after each 
drug administration before ischemia, while this time interval was 
2 min at the beginning of reperfusion.
For each experimental group nine animals (five for group S) 
were used for microvascular studies, 15 for the assessment of 
E-selectin expression, 10 animals for quantitative determination 
of oxidative stress by evaluation of thiobarbituric acid-reactive sub-
stances (TBARS) and six hamsters were used for measurement of 
2′-7′-dichlorofluorescein (DCF) fluorescence.
cheek pouch preparatIon
Animals  were  anesthetized  (pentobarbital  sodium  5  mg/100  g 
body weight i.p.) and tracheostomized. The right carotid artery 
and femoral vein were cannulated to measure blood pressure and 
administer additional anesthesia and fluorescent tracers. The cheek 
pouch was surgically prepared as previously reported (Bertuglia 
and Colantuoni, 2000). In brief, the membrane was gently everted 
and fixed to a special stage adapted to the microscope; a thin black 
blade was inserted through a small incision between the upper and 
lower layers of the pouch, thus preserving the epithelial cells. The 
membrane was suffused with Ringer solution (in mM: 137 NaCl, 
4.7 KCl, 1.2 MgSO4, 2.0 CaCl2, 18.0 NaHCO3) at 36.0 ± 0.5°C with 
5% CO2–95% N2 adjusted to pH 7.35.
Atraumatic microvascular clips were placed for 30 min on the 
proximal part of the cheek pouch to achieve complete ischemia. 
After  removing  clamp,  the  microcirculation  was  observed  for 
30 min (reperfusion).
All experiments conform to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of 
Health (NIH Publication No. 85.23, revised 1996) and to institu-
tional rules for the care and handling of experimental animals.
Fluorescence mIcroscopy
Observations of microcirculation were made with a fluorescence 
microscope (Leitz Orthoplan) with objectives 4×, numerical aper-
ture (NA) 0.14; 20×, NA 0.25; 32×, NA 0.40; 40×, NA 0.30, a 10× 
eyepiece and a filter block (Ploemopak, Leitz). Epi-illumination was 
provided by a 100-W mercury lamp using the appropriate filters 
for fluorescein isothiocyanate (FITC) bound to dextran (molecular 
weight 150 kDa, 50 mg/100 g body weight i.v. as 5% wt/vol solution 
in 5 min) (FD 150) (Sigma Chemical), for rhodamine 6G and a 
heat filter (Leitz KG1). The animals received an intravenous injec-
tion of 1 mg rhodamine 6G/100 g body weight in 0.3 ml (Sigma 
Chemical) and a supplemental injection (final volume 0.3 ml × 100 
per g per × h) throughout the experiment to label leukocytes for 
adhesion evaluation.
The area of interest was televised with a DAGE MTI 300 low-
light level digital camera and observed from a Sony PVM 122 CE 
monitor. Video images were videotaped and microvascular meas-
urements were made off-line using a computer-assisted imaging 
software system (MIP Image, CNR, Institute of Clinical Physiology, 
Pisa, Italy).
Although all these clinical and experimental data demonstrate 
that pLc exerts beneficial effects in different pathologies involv-
ing several organ systems, to date there is no direct evidence to 
determine the effects of pLc on the microcirculation during I/R 
damage. In particular, there is no consensus concerning the mecha-
nisms through which pLc prevents the microvascular permeability 
increase and improves the supply of blood flow to tissues.
Therefore, the present study was carried out to assess the main 
effects of intravenously and topically applied pLc on microvas-
cular alterations induced by I/R. The hamster cheek pouch was 
chosen as the experimental model that permits in vivo observa-
tion of the microvascular changes during ischemia and subsequent 
reperfusion.
The objective of this paper was to evaluate the microvascular 
permeability increase and the role of leukocytes into I/R-induced 
damage. These events are strictly correlated because leukocyte 
activation and successive adhesion in post-capillary and collect-
ing venules represents the background for the consequent vascu-
lar endothelial damage. In particular, we tried to assess the effects 
of inhibiting nitric oxide release or endothelium-derived hyper-
polarizing factor (EDHF) effect on microvascular permeability. 
Therefore,  we  tested  the  effects  of  NG-nitro-l-arginine-methyl 
ester (l-NAME), inhibitor of nitric oxide synthase (NOS), and 
Apamin plus Charybdotoxin (inhibitors of both BKCa and voltage-
sensitive potassium channels) on microvascular changes resulting 
from I/R injury.
Finally, to clarify the role of leukocyte activation on perme-
ability increase (Carlos and Harlan, 1994; Billups et al., 1995; Ley 
et al., 1998) during pLc treatment, we determined the expression 
of E-selectin, known to mediate leukocyte rolling and to participate 
in the conversion of rolling to firmly adhering leukocytes.
materIals and methods
experImental groups
Studies were performed on male Syrian hamsters (80–100 g) 
(Charles River, Calco, Italy) that were randomly assigned to seven 
groups: (1) Sham-operated group (Group S, n = 36): hamsters 
subjected to the same procedures as the experimental groups 
except for clamping of the cheek pouch. (2) Control hamsters 
(Group C, n = 40) were treated with topically applied vehicle and 
subjected to 30 min of ischemia and 30 min of reperfusion. (3) 
The third group of animals (sub-group P1a and sub-group P1b, 
n = 40 for each sub-group) received intravenously 2 mg/100 g 
body wt or 5 mg/100 g body wt of pLc in 2 min, starting 10 min 
before ischemia and at the beginning of reperfusion. (4) The 
fourth group of hamsters (sub-group P2a and sub-group P2b, 
n = 40 hamsters for each group) was treated with topically applied 
1.5 or 2.5 mM pLc in 2 min, starting 10 min before ischemia and 
for 2 min at the beginning of reperfusion. (5) The fifth group of 
animals (group P3, n = 40 hamsters) was treated with topically 
applied 1 mM l-NAME in 2 min prior to the topical administra-
tion of 2.5 mM pLc in 2 min, starting 20 min before ischemia 
and at the beginning of reperfusion, with a time interval of 
8 min between each drug administration. (6) The sixth group of 
hamsters (P4, n = 40) was treated with topically applied Apamin 
(0.3 μM) plus Charybdotoxin (0.1 μM) in 2 min, 10 min prior 
to pLc (2.5 mM), starting 20 min before ischemia and at the www.frontiersin.org  October 2010  | Volume 1  | Article 132  |  3
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used to localize the antigen. As a negative control, the primary 
antiserum was substituted by 1/20 normal goat serum or PBS. 
FITC (Jackson ImmunoResearch) was used to reveal the antigens 
as needed.
The sections were then mounted with phenylenediamine/glyc-
erine/PBS medium and viewed with a Leitz Diaplan fluorescence 
microscope.
rna extractIon and rt-pcr assay
Five hamsters were used for each experimental group. RNA was 
extracted from tissues by Trizol™ (Invitrogen). Random primed 
double-strand  cDNA  was  synthesized  using  Superscript  III 
(Invitrogen). The specificity of each oligonucleotide pair used was 
verified with the BLAST program.
The  amplification  conditions  for  each  primer  pair  were 
experimentally  determined.  From  20  to  40  amplification 
cycles  were  run  to  avoid  saturating  conditions.  E-selectin  was 
analyzed  by  amplifying  1  μl  of  the  resulting  cDNA  with  the 
following oligonucleotides based on the murine sequence: for-
ward,  5′-CCTCGACAGAGGAAGCTCAGAACT-3′;  reverse, 
5′-TCCACTCTCCAGAGGACGTACACCG-3′ ( Yao  et  al.,  1991; 
Milstone et al., 2000).
The  PCR  conditions  used  were  the  following:  35  cycles  at 
94°C for 1 min, 68°C for 1 min, and 72°C for 1 min. The ampli-
fication product of 374 bp was run on 2.0% agarose gel in TAE 
buffer and visualized by ethidium bromide staining. The inten-
sity of the amplified bands was quantified by densitometry and 
referred to that obtained with glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH). These last specific primers were: forward: 
5′-GACCCCTTCATTGACCTCAACTACATG-3′,  and  reverse: 
5′-GTCCACCACCCTGTTGCTGTAGCC-3′. The PCR condition 
for GAPDH were as follows: 25 cycles at 94°C for 1 min, 60°C for 
1 min, and 72°C for 1 min.
Western blot and antIbodIes
Protein extracts were obtained from tissues (n = 5 hamster per 
group) after homogenization at 4°C in RIPA buffer (Radioimmuno 
precipitation assay) containing protease inhibitors (Roche Applied 
Science), using an Ultra-Turrax (IKA; Labortechnik) (Yao et al., 
1991). Protein concentration was determined by Bradford assay 
(Rio-Rad). Protein extracts (50–70 μg) were run on a 7% SDS–
PAGE and transferred onto polyvinylidene difluoride membranes. 
Immunodetection was performed with the primary antibodies 
(dilution: 1:500) followed by incubation with peroxidase-  conjugated 
secondary antibody, using the enhanced chemiluminescence detec-
tion reagent (Amersham Biosciences).
Protein loading was normalized by incubating the same filters 
with anti-β-actin antibody.
The band intensity was quantified by densitometry (Bio-Rad). 
The antibodies used in Western blot analysis were: m E-selectin 
(Santa Cruz Biotechnology) and β-actin A1978 (Sigma).
tbars measurements
The tissue content of thiobarbituric acid reactive substances, as 
an index of lipid peroxidation, was determined according to the 
method previously reported (Granger, 1999). Briefly, 0.25 g of cheek 
pouch membrane were homogenized in 5% trichloroacetic acid, in 
Microvascular observations were carried out for 1 min every 
5 min during application of drugs; then, every 10 min during I/R.
mIcrovascular parameters evaluatIon
Macromolecular leakage was manifested by extravasation of FITC–
dextran, which appeared as fluorescent spots outside microvessels. 
Therefore, the increase in permeability was calculated and reported 
as normalized gray levels (NGL): NGL = (I − Ir)/Ir, where Ir is the 
average baseline gray level at the end of vessel filling with fluorescence 
(average of five windows located outside the blood vessels with the 
same windows being used throughout the experimental procedure), 
and I is the same parameter after ischemia or reperfusion. Gray levels 
ranging from 0 to 255 were determined by the MIP Image program 
in five regions of interest (ROI) measuring 50 × 50 μm.
The  endothelial  dysfunction  causes  a  reduction  of  tissue 
perfusion that involves mainly the capillary network. The per-
fused capillary length was measured by MIP Image in an area of 
550 × 550 μm. In this experimental system, the length of perfused 
capillaries is easily established by the automated process because 
it is outlined by dextran.
Adherent leukocytes highlighted with rhodamine 6G (i.e., cells 
on vessel walls that did not move over a 30-s observation period) 
were quantified in terms of numbers/100 μm venular length/30 s.
Vessel diameters and capillary red blood cell velocity (VRBC) 
were measured with a computer-assisted method (frame by frame). 
The results of diameter measurements were in accord with those 
obtained by shearing method (±0.5 μm). To avoid bias due to sin-
gle operator measurements, two independent “blinded” operators 
determined  all  the  measured  parameters.  Their  measurements 
overlapped in all cases.
Under baseline conditions, the cheek pouch arterioles were clas-
sified according to centrifugal ordering scheme from the largest 
(A1) to the smallest (A4) arterioles. We investigated the responses 
of each arteriolar order to the experimental conditions: at the end 
of ischemia (EI) and at the end of reperfusion (ER) compared 
with the baseline conditions. In each hamster, two A2, two A3, and 
two A4 arterioles were studied during each experiment; because of 
homogenous responses in all arteriolar orders, we chose to present 
only the data regarding A2 larger vessels.
Mean  arterial  blood  pressure  (MABP)  (Viggo-Spectramed 
P10E2 transducer – Oxnard, CA, USA – connected to a catheter 
in the carotid artery) and heart rate were monitored with a Gould 
Windograf recorder (model 13-6615-10S, Gould, OH, USA). Data 
were recorded and stored in a computer.
ImmunoFluorescence
For immunocytochemistry, hamsters (n = 5 for each experimental 
group) were anaesthetized with pentobarbital (5 mg/100 g body 
weight), perfused with 0.5% sodium nitrite and then with 10% 
buffered formalin. Cheek pouches were carefully removed and kept 
for further 2–3 h in the same fixative. Specimens were then left 
under refrigeration at 4°C in 30% sucrose in phosphate buffered 
saline (PBS) for 48 h and embedded in OCT medium before freez-
ing and cryostat sectioning.
Cryostat sections (10-μm-thick) were processed for the indi-
rect immunofluorescence method (Coons, 1971). Goat anti-rat 
E-selectin antibody (R&D Systems, Inc.; dilution 15 μg/ml) was Frontiers in Physiology  |  Vascular Physiology    October 2010  | Volume 1  | Article 132  |  4
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age of FD 150 (Figure 2) and leukocyte adhesion was pronounced 
in post capillary and connecting venules (11.0 ± 1.2/100 μm of 
venular length/30 s, p < 0.01 vs. baseline: 1 ± 0.5/100 μm of venular 
length/30 s) (Figure 4). The perfused capillary length was reduced 
by 63.0 ± 1.1% of baseline (p < 0.01 vs. baseline) (Table 2) and capil-
lary VRBC was 0.210 ± 0.005 mm/s (p < 0.01 vs. baseline) (Table 1). 
A2 arteriolar diameter significantly decreased compared with the 
baseline (Figure 3).
plc-treated anImals
Intravenously infused pLc (2 and 5 mg/100 g body wt) dose-
  dependently protected microvascular networks. At EI, leakage was 
prevented (0.14 ± 0.01 and 0.13 ± 0.01 NGL, p < 0.01 vs. controls, 
respectively) (Figures 1 and 2). A2 arteriolar diameter (P1a–P1b 
sub-groups diameter: 21.7 μm, 19.7–24.3 μm, and 23.0 μm, 20.5–
25.3 μm; n = 18 for each group, respectively) did not significantly 
change compared with baseline at both dosages (Figure 3). At 
ER, microvascular leakage was reduced compared with control 
(0.34 ± 0.02 and 0.28 ± 0.03 NGL, respectively, p < 0.01 vs. con-
trols) (Figures 1 and 2). Adhesion of leukocytes was prevented 
(5.0 ± 1.1 and 4.5 ± 0.6/100 μm of venular length/30 s, respec-
tively, p < 0.01 vs. controls) (Figure 4), while the perfused capillary 
length was reduced by 30.0 ± 1.4% and 25.0 ± 1.7% of baseline, 
according to the doses (p < 0.01 vs. controls) (Table 2). Capillary 
VRBC was 0.260 ± 0.010 and 0.320 ± 0.008 mm/s with both dos-
ages, respectively (p < 0.01 vs. baseline and controls) (Table 1). 
Finally, A2 arteriolar diameter significantly increased compared 
with baseline (Figure 3).
pLc  (1.5  and  2.5  mM/l)  topically  applied  on  cheek  pouch 
membrane determined the same protective effects as observed 
with intravenous administration. At EI, pLc dose-dependently 
prevented permeability increase (0.15 ± 0.01 and 0.10 ± 0.01 
presence of butylated hydroxytoluene (0.01%) and 1 mM EDTA 
to avoid lipid peroxidation during assay. The precipitate was pel-
leted by centrifugation (3000 rpm for 15 min) and an aliquot of 
the supernatant was reacted with an equal volume of 0.67% (w/v) 
thiobarbituric acid. Subsequently, the samples were heated at 80°C 
for 30 min and after cooling the absorption at 532 nm was meas-
ured. TBARS were expressed as malondialdehyde (MDA) amount 
using freshly diluted MDA bisdimethylacetal as standard. TBARS 
in cheek pouch membrane was evaluated at different times: at the 
end of ischemia and at 20 min of reperfusion.
2′-7′ dIchloroFluoresceIn (dcF) Fluorescence measurements
Ringer  solution  containing  12  μM  2′-7′-dichlorofluorescein-
diacetate (DCFH-DA) was superfused for 20 min on the cheek 
pouch prior to ischemia. The lipophilic DCFH-DA diffuses across 
the cell membranes and is retained into the intracellular space, 
converted to membrane impermeable non-fluorescent DCFH. This 
substance is oxidized by intracellular hydrogen peroxide (H2O2) 
to yield DCF, a high fluorescent molecule. This reaction is revers-
ible and the intensity of DCF fluorescence is proportional to the 
intracellular ROS levels. The fluorescence intensity was determined 
by using an appropriate filter (522 nm); then NGL were evalu-
ated, comparing the fluorescence at the end of ischemia (n = 3) or 
reperfusion (n = 3) with the baseline represented by fluorescence 
of the cheek pouch just superfused with DCFH-DA.
statIstIcal analysIs
All reported values are means ± SEM. The data were analyzed for 
their statistical significance. The Gaussian distribution of data was 
examined by Kolmogorov–Smirnov (KS) test. Paired and unpaired 
Student’s t-test, ANOVA, and Bonferroni’s post hoc test were used in 
the case of normal distribution; when the data were not normally 
distributed Mann–Whitney U test and Kruskal–Wallis test were 
utilized for non-parametric testing of null hypothesis. The changes 
in diameter and DCF fluorescence were analyzed by non-paramet-
ric tests, because KS test indicated non-Gaussian distribution of 
these data. Diameter data were presented as median (minimum and 
maximum diameter). Statistical significance was set at p < 0.05.
results
In all experimental groups the cheek pouch arterioles were classified 
according to centrifugal scheme, starting from the largest arterioles 
A1 (median diameter: 30.0 μm; minimum and maximum 26.0–
34.0 μm, n = 77), to the smaller A2 (22.5 μm; 19.3–25.7 μm, n = 154), 
and A3 arterioles (15.0 μm; 10.5–19.5 μm, n = 154) to the smallest 
ones A4 (7.9 μm; 6.8–9.4 μm, n = 154) in the preparation.
Under baseline conditions in the cheek pouch microvascular 
networks of sham-operated animals there was no leakage of fluo-
rescence dextran nor leukocyte adhesion, while all capillaries were 
perfused and capillary VRBC was 0.200 ± 0.005 mm/s (Table 1).
I/r In control hamsters
In  control  hamsters  30  min  of  ischemia  caused  an  increase 
in FD 150 permeation (0.31 ± 0.03 NGL, p < 0.01 vs. baseline) 
(Figures 1and 2). A2 arterioles (median diameter: 23.0 μm, mini-
mum and maximum: 20.6–25.7 μm, n = 18) showed a significant 
decrease in diameter (Figure 3). At ER, there was a marked leak-
Table 1 | Capillary red blood cell velocity (VRBC) under baseline 
conditions (B) and after reperfusion (R) in all experimental groups.
Groups  VRBC (mm/s)  n
  B  R 
S  0.200 ± 0.005  –  25
C  0.200 ± 0.005  0.210 ± 0.005a  45
P1a  0.210 ± 0.005  0.260 ± 0.010a,b  45
P1b  0.205 ± 0.005  0.320 ± 0.008a,b  45
P2a  0.200 ± 0.005  0.250 ± 0.005a,b  45
P2b  0.210 ± 0.005  0.290 ± 0.009a,b  45
P3  0.205 ± 0.005  0.220 ± 0.005a  45
P4  0.210 ± 0.005  0.190 ± 0.010a,b  45
P5  0.200 ± 0.005  0.200 ± 0.010a  45
S, sham-operated group; C, control group; P1a, hamsters treated with pLc intrave-
nously infused, lower concentration; P1b, hamsters treated with pLc intrave-
nously infused, higher concentration; P2a, animals treated with pLc topically 
applied, lower concentration and P2b, animals treated with pLc topically applied, 
higher concentration; P3, animals treated with topical application of  l-NAME 
prior to pLc higher concentration; P4, hamsters treated with topical application 
of Apamin and Charybdotoxin prior to pLc higher concentration; P5, hamster 
treated  with  topical  application  of  l-NAME  plus  Apamin  and  Charybdotoxin 
prior to pLc higher concentration. n, number of studied capillaries. ap < 0.01 vs. 
baseline; bp < 0.01 vs. control group.www.frontiersin.org  October 2010  | Volume 1  | Article 132  |  5
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nos InhIbItIon plus plc
The topical application of l-NAME (1 mM) prior to pLc (2.5 mM/l) 
(P3 group) caused a slightly increase in leakage (0.18 ± 0.02 NGL, 
p < 0.01 vs. controls), higher when compared with hamsters treated 
only with pLc (P2b sub-group) at EI (Figure 2). A2 arteriolar diam-
eter (23.7 μm, 20.8–25.7 μm, n = 18) significantly decreased com-
pared with baseline (Figure 3). At ER, microvascular permeability 
further increased and was significantly different compared with 
that observed in P2b group (0.34 ± 0.01 NGL, p < 0.01 vs. control) 
(Figure 2). The leukocyte adhesion decreased (6.0 ± 0.9/100 μm of 
venular length/30 s, p < 0.01 vs. controls) as well as the perfused 
capillary length (by 38.0 ± 1.1% of baseline, p < 0.01 vs. controls) 
(Figure 4 and Table 2).The capillary VRBC was 0.220 ± 0.005 mm/s 
(p < 0.01 vs. baseline) (Table 1) and A2 arteriolar diameter was 
significantly reduced compared with the baseline (Figure 3).
NGL, respectively, p < 0.01 vs. controls). A2 arteriolar diameter 
(P2a–P2b  sub-groups  diameter:  23.1  μm,  20.2–25.7  μm,  and 
22.3 μm, 19.3–25.2 μm; n = 18 for each group, respectively) did 
not significantly change compared with baseline at both dosages 
(Figure 3). At ER, the leakage was prevented compared with con-
trol group (0.35 ± 0.01 and 0.26 ± 0.02 NGL, respectively, p < 0.01 
vs. controls) (Figures 1 and 2). The number of adherent leuko-
cytes significantly decreased (5.5 ± 0.6 and 4.0 ± 0.4/100 μm of 
venular length/30 s, respectively, p < 0.01 vs. controls) (Figure 4). 
Moreover, the perfused capillary length diminished by 36.0 ± 0.9% 
and 27.0 ± 1.2% of baseline, respectively (p < 0.01 vs. controls) and 
capillary VRBC was 0.250 ± 0.005 and 0.290 ± 0.009 mm/s with both 
dosages, respectively (p < 0.01 vs. baseline and controls) (Tables 1 
and 2). A2 arteriolar diameter significantly increased compared 
with baseline (Figure 3).
FiGuRE 1 | Computer-assisted images of a microvascular networks in 
control hamster under baseline conditions (A) and at the end of reperfusion 
(B); in hamster treated with pLc, 5 mg/100 g body wt intravenously injected 
(C,D), and in hamster treated with pLc 2.5 mM/l topically applied (E,F), at the 
same time points as in control. The increase in permeability is apparent by the 
marked changes in the color of interstitium (from black to white). pLc prevented 
the increase in permeability because the interstitium did not significantly change 
in color (black). Scale bar = ___ 50 µm.Frontiers in Physiology  |  Vascular Physiology    October 2010  | Volume 1  | Article 132  |  6
Lapi et al.  Propionyl-l-carnitine and ischemia–reperfusion
apamIn and charybdotoxIn plus plc
Apamin  (0.3  μM)  and  Charybdotoxin  (0.1  μM)  prior  to  pLc 
(2.5 mM) topically applied on cheek pouch membrane abolished 
the pLc-induced effects. At EI, NGL increased up to 0.29 ± 0.02 
(p < 0.01 vs. baseline and P2b sub-group) (Figure 2), while arte-
riolar diameter (22.5 μm, 19.3–25.5 μm, n = 18) did not change 
compared with that detected in P2b sub-group (Figure 3). At ER, 
NGL increased up to 0.57 ± 0.03 (p < 0.01 vs. baseline and P2b sub-
group); the leukocyte adhesion was pronounced (10.0 ± 0.9/100 μm 
of venular length/30 s, p < 0.01 vs. baseline and P2b sub-group) 
(Figure 3). Moreover, the perfused capillary length decreased by 
The  topical  application  of  l-NNA  (1  mM)  prior  to  pLc 
(2.5 mM/l) caused the same microvascular effects as l-NAME 
treatment, as observed in preliminary experiments.
FiGuRE 2 | Permeability increase after ischemia (i) (left) and reperfusion 
(R) (right) in the experimental groups: S, sham-operated group; C, control 
group; P1a, hamsters treated with propionyl-l-carnitine (pLc) 
intravenously infused, lower concentration; P1b, hamsters treated with 
pLc intravenously infused, higher concentration; P2a, animals treated 
with pLc topically applied, lower concentration and P2b, animals treated 
with pLc topically applied, higher concentration; P3a, animals treated 
with topical application of l-NAME prior to pLc higher concentration; P4, 
hamsters treated with topical application of Apamin and Charybdotoxin 
prior to pLc higher concentration; P5, hamsters treated with topical 
application of l-NAME plus Apamin and Charybdotoxin prior to pLc 
higher concentration. In S group, data were evaluated at 45 and 75 min of 
observation. NGL, normalized gray levels. °p < 0.01 vs. sham-operated group, 
*p < 0.01 vs. C group, **p < 0.01 vs. P2b group.
FiGuRE 3 | Percent diameter changes of A2 arterioles, at the end of 
ischemia (left column, Ei) and at the end of reperfusion (right column, 
ER) in the experimental groups, as reported in Figure 2 legend. °p < 0.01 
vs. sham-operated group, *p < 0.01 vs. C group.
FiGuRE 4 | Leukocyte adhesion to venular walls at the end of reperfusion 
in the experimental groups, as reported in Figure 2 legend. °p < 0.01 vs. 
sham-operated group, *p < 0.01 vs. C group, **p < 0.01 vs. P2b group.
Table 2 | The perfused capillary length under baseline conditions (B) and 
percent changes at the end of reperfusion (R) in the experimental 
groups.
Groups  Perfused capillary   Decrease R 
  length (μm %)
  B  R 
S  9670 ± 115  –  –
C  9550 ± 135  3534 ± 41  63.0 ± 1.1 a
P1a  9850 ± 127  6895 ± 57  30.0 ± 1.4 a,b
P1b  9520 ± 147  7140 ± 92  25.0 ± 1.7 a,b
P2a  9700 ± 101  6208 ± 53  36.0 ± 0.9a,b
P2b  9580 ± 119  6994 ± 80  27 .0 ± 1.2 a,b
P3  9720 ± 106  6027 ± 72  38.0 ± 1.1 a,b
P4  9800 ± 110  4116 ± 65  58.0 ± 1.7 a,b
P5  9680 ± 100  3388 ± 90  65.0 ± 1.4 a,b
S, sham-operated group; C, control group; P1a, hamsters treated with pLc intrave-
nously infused, lower concentration; P1b, hamsters treated with pLc intrave-
nously infused, higher concentration; P2a, animals treated with pLc topically 
applied, lower concentration and P2b, animals treated with pLc topically applied, 
higher concentration; P3, animals treated with topical application of  l-NAME 
prior to pLc higher concentration; P4, hamsters treated with topical application 
of Apamin and Charybdotoxin prior to pLc higher concentration; P5, hamster 
treated with topical application of l-NAME plus Apamin and Charybdotoxin prior 
to pLc higher concentration. ap < 0.01 vs. baseline; bp < 0.01 vs. control group.www.frontiersin.org  October 2010  | Volume 1  | Article 132  |  7
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58.0 ± 1.7% of baseline (p < 0.01 vs. baseline and P2b sub-group) 
as well as capillary VRBC (0.190 ± 0.010 mm/s) (p < 0.01 vs. baseline 
and controls) (Tables 1 and 2). A2 arteriolar diameter did not sig-
nificantly change compared with control group (Figure 3).
nos InhIbItIon, apamIn and charybdotoxIn plus plc
Finally, the last group of hamsters treated with l-NAME (1 mM) 
plus Apamin (0.3 μM) and Charybdotoxin (0.1 μM) prior to pLc 
(2.5 mM), topically administered, abolished the pLc-induced effects. 
At EI, the leakage of FD 150 was marked (0.30 ± 0.02 NGL, p = NS 
vs. controls) and A2 arterioles (22.8 μm, 19.8–25.6 μm, n = 18), 
significantly constricted compared with baseline (Figure 3). At 
ER, the microvascular permeability was pronounced (0.65 ± 0.03 
NGL, p = NS vs. controls), the leukocyte adhesion was marked 
(11.0 ± 1.1/100 μm of venular length/30 s, p < 0.01 vs. baseline) 
and the perfused capillary length decreased by 65.0 ± 1.4% of base-
line (p = NS vs. controls) (Figures 2 and 4, Table 2). Capillary 
VRBC was 0.200 ± 0.010 mm/s (p < 0.01 vs. baseline) (Table 1). A2 
arteriolar diameter significantly decreased compared with baseline 
(Figure 3).
Moreover, there were no significant changes in MABP and heart 
rate (HR) among the different groups in baseline conditions, at 
EI and at ER.
In vItro analysIs
E-selectin expression was assessed by immunocytochemistry in 
either sham-operated or -control or -treated hamsters. In these last 
animals, pLc was administered either intravenously or topically at the 
highest dosage. E-selectin was not detected in cheek pouch prepara-
tions in sham-operated hamsters under baseline conditions. At ER 
in control hamsters, instead, E-selectin was detected along the vessel 
walls, as accumulated fluorescent spots. Interestingly, administration 
of pLc was effective in reducing accumulation of protein along the 
vessel walls. The topical administration of l-NAME or Apamin and 
Charybdotoxin or l-NAME plus Apamin and Charybdotoxin prior 
to pLc (groups P3, P4, and P5) increased fluorescent spots indicating 
E-selectin expression on vessel walls.
To further assess E-selectin gene expression in the experimental 
conditions used, RT-PCR and Western blot analyses were carried 
out. Under baseline conditions in sham-operated hamsters we 
could not detect a specific product by RT-PCR, indicating that the 
E-selectin gene was not actively transcribed. Conversely, at RE, a 
specific amplified product of E-selectin gene was obtained in ham-
sters subjected to I/R, as shown in Figure 5. This band was reduced 
in intensity by the higher dosage of pLc applied both systemically 
or topically (sub-groups P1b and P2b). On the contrary, the topi-
cal administration of l-NAME or Apamin and Charybdotoxin or 
l-NAME plus Apamin and Charybdotoxin prior to pLc (groups 
P3, P4, and P5) increased the band intensity corresponding to 
E-selectin expression.
These results were confirmed by Western blot analysis on pro-
tein extracts from sham-operated or control or pLc-treated cheek 
pouch preparations. Under basal conditions in sham-operated ani-
mals, we could not detect any E-selectin. After reperfusion a band of 
the expected molecular weight was clearly detectable, whose inten-
sity was significantly reduced by the higher dosage of pLc applied 
both systemically or topically. Cheek pouch preparations topically 
FiGuRE 5 | Treatment with topically applied pLc (2.5 mM/l) reduces the 
formation of mRNA for E-selectin (upper) and the expression of E-selectin 
(lower) (A). S, sham-operated; P2b (pLc, 2.5 mM/l, topically applied treated 
animal); C (I/R control hamster); P3 (l-NAME plus pLc treated hamster), P4 
(Apamin- and Charibdotoxin-treated hamster); P5 (l-NAME and Apamin and 
Charibdotoxin plus pLc-treated hamster. The intensity of mRNA amplified 
bands was referred to that obtained with glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Changes in the E-selectin mRNA concentration 
expressed as relative units (B). E-selectin protein loading was normalized by 
incubating the same filters with anti-β-actin antibody. Changes in the E-selectin 
protein concentration expressed as relative units (C). *p < 0.01 vs. control and 
the other experimental groups. °p < 0.01 vs. sham-operated group.Frontiers in Physiology  |  Vascular Physiology    October 2010  | Volume 1  | Article 132  |  8
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  pattern was observed at the end of reperfusion, where pLc blunted 
leukocyte adhesion and preserved capillary perfusion inducing arte-
riolar dilation when compared with controls. Moreover, E-selectin 
expression was reduced, as observed with immunohistochemical 
analysis, RT-PCR assay, and Western blot.
The features of I/R injury are marked reduction in blood flow 
and leukocyte adhesion. Our data indicate that most cheek pouch 
capillaries were devoid of blood flow at the end of reperfusion. The 
permeability increase indicates that the vessel wall function was 
impaired. pLc protected vessel walls probably by NO and EDHF 
release. However, Apamin and Charybdotoxin administration prior 
to pLc caused marked leakage, higher than after l-NAME admin-
istration prior to pLc.
treated with l-NAME or Apamin and Charybdotoxin or l-NAME 
plus Apamin and Charybdotoxin prior to pLc (groups P3, P4, and P5) 
showed a band corresponding to E-selectin production (Figure 5).
tbars
The sequence of events that cause lipoperoxidation in the cheek 
pouch membrane was monitored by determination of TBARS at 
the end of ischemia and during reperfusion on the homogenate of 
the cheek pouch. Pilot studies carried out in animals submitted to 
ischemia–reperfusion indicated that TBARS peaked at 15–20 min 
of reperfusion. In sham-operated animals there were no significant 
amounts of TBARS.
At  EI  in  control  hamsters  (C  group)  TBARS  increased  by 
57.0 ± 3.2% of baseline MDA, as quantified in contralateral cheek 
pouch, while at 20 min of reperfusion increased by 60.5 ± 3.5% of 
baseline MDA (Figure 6). The higher dosage of pLc applied both 
systemically or topically caused a marked reduction in TBARS com-
pared with controls: at EI and at 20 min of reperfusion TBARS did 
not significantly change compared with contralateral cheek pouch 
MDA (1.5 ± 0.2% MDA and 1.3 ± 0.1% MDA, respectively, p < 0.01 
vs. control hamsters) (Figure 6).
l-NAME prior to pLc, topically administered, abolished the pLc 
protective effects because MDA amount increased by 55.0 ± 2.6% and 
56.7 ± 2.3%, at EI and at 20 min of reperfusion, respectively (p = NS 
vs. controls). The same effects were induced by topical administra-
tion of Apamin and Charybdotoxin or l-NAME plus Apamin and 
Charybdotoxin prior to pLc (P4 and P5 groups). At EI, TBARS 
increased by 58.0 ± 2.9% MDA and 59.5 ± 2.7% MDA, respectively 
(p = NS vs. controls); after 20 min of reperfusion TBARS increased 
by 72.0 ± 3.2% and 78.0 ± 2.9% MDA compared with contralateral 
cheek pouch, respectively (p = NS vs. controls) (Figure 6).
dcF Fluorescence
Finally, the superfusion of the cheek pouch with DCFH-DA in 
animals submitted to I/R induced an increase in fluorescence in 
control animals, especially at ER (1.01 ± 0.04 NGL, p < 0.01 vs. base-
line) (Figure 7). Higher dosage of pLc, intravenously and topically 
applied (P1b and P2b sub-groups) significantly reduced fluorescence 
of membrane at ER (0.23 ± 0.03 NGL and 0.22 ± 0.04 NGL, respec-
tively, p < 0.01 vs. controls). The fluorescence intensity was amplified 
in the cheek pouch preparations treated with l-NAME or Apamin 
and Charybdotoxin or l-NAME, Apamin, and Charybdotoxin prior 
to pLc (groups P3, P4, and P5) (0.90 ± 0.01 NGL, 0.95 ± 0.02 NGL 
and 1.08 ± 0.02 NGL, respectively, p = NS vs. controls).
dIscussIon
The results of the present study indicate that I/R caused the micro-
circulation of hamster cheek pouch to be severely compromised 
because of an increase in leakage following I/R. Moreover, com-
pared to baseline there was pronounced leukocyte adhesion in 
post capillary and connecting venules; the capillary blood flow was 
markedly impaired and the arterioles constricted. By immunohisto-
chemical analysis microvessels presented an increased expression of 
E-selectin as well as an increase in mRNA transcript and protein.
pLc both topically or intravenously administered, exerted dose-
dependent protective effects on the cheek pouch microcirculation 
during I/R. pLc prevented leakage during ischemia. The same 
FiGuRE 6 | Changes in thiobarbituric acid reactive substances (TBARS) in 
homogenate of the cheek pouch expressed as percent changes of 
malondialdehyde (MDA) at the end of ischemia (left column, Ei) and after 
20 min of reperfusion (right column) in the experimental groups, as 
reported in Figure 2 legend. °p < 0.01 vs. sham-operated group, 
*p < 0.01 vs. C group.
FiGuRE 7 | Changes in DCF fluorescence intensity correlated to the 
intracellular reactive oxygen species (ROS) levels at the end of 
reperfusion (ER) in the experimental groups, as reported in Figure 2 
legend. °p< 0.01 vs. sham-operated group, *p < 0.01 vs. C group.www.frontiersin.org  October 2010  | Volume 1  | Article 132  |  9
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Leukocyte adherence to the endothelium represents a key event 
in I/R injury. E-selectin has been shown to mediate leukocyte rolling 
and participate in the rolling conversion to ones firmly adhered. 
This molecule, indeed, occurs in the first phase of I/R damage 
(Carlos and Harlan, 1994; Billups et al., 1995; Ley et al., 1998). 
E-selectin expression in the vascular bed appears to be inhomoge-
neous, because of differences between endothelium in large versus 
small vessels in their ability to express these proteins. Our data show 
that E-selectin expression increased during reperfusion and was 
confined to endothelial cells lining post-capillary venules.
The increase of adhesion molecules expression accompanied 
by adherence of leukocytes to peripheral circulation endothelium 
may contribute to changes in vascular permeability. Our data sup-
port the hypothesis that E-selectin biosynthesis and expression are 
associated with ischemia and re-oxygenation because E-selectin 
expression was absent in hamsters not subjected to I/R.
Interestingly, as reported in previous studies, pLc shows O2
− and 
·OH scavenging activity. Our results indicate that pLc reduced for-
mation of ROS, as indicated by the decrease in TBARS at the end of 
ischemia and at 20-min reperfusion. The percent increase in TBARS 
compared with baseline in control hamsters was higher at 20-min 
reperfusion, but it is worth noting at the end of ischemia appeared also 
an increase in TBARS. However, pLc counterbalanced the increase in 
TBARS both at the end of ischemia and at 20-min reperfusion. Our 
data are the first results reported on the cheek pouch tissue TBARS, 
measured at the end of ischemia and at 20-min reperfusion. Therefore, 
the increase in ROS and E-selectin production indicate that ROS might 
increase E-selectin expression with higher formation of mRNA and 
gene products. Our results support previous studies showing that 
E-selectin expression is triggered by ROS (Mondola et al., 1998).
The effect on ROS formation exerted by pLc was accompanied 
by preservation of NO release and the protection of NO effects 
on vascular smooth muscle cells and platelets. The summation of 
these effects could facilitate preservation of microvascular networks 
assuring tissue oxygenation. Our data indicate that capillary blood 
flow was preserved, with an increased capillary perfusion, when 
compared with control, and increased RBC velocity in capillaries. 
Previous data indicate that pLc improves arterial perfusion (Alvarez 
de Sotomayor et al., 2007). The effects on arterial diameter likely 
due to preserved NO and EDHF release, as shown also by Kajiya 
et al. (2007) and Karmakar (2001) and the reduction of E-selectin 
expression, may be the basis for increased capillary perfusion and 
capillary RBC velocity as indicated by our results.
The effect of pLc on ROS is supported by our results on DCF fluo-
rescence that was significantly decreased by pLc at the end of reper-
fusion. Therefore, E-selectin reduction expression appears to be due 
to the decreased formation of ROS caused by pLc, with consequent 
blunted formation of mRNA for the protein and reduction of pro-
tein adduct. These results support previous data on the reduction of 
circulating adhesion molecules observed under different pathophysi-
ological conditions (Signorelli et al., 2001; Silvestro et al., 2006).
Our results confirm the recovery of the capillary blood flow that 
has been reported in hepatic warm ischemia–reperfusion treated 
with pLc. Yonezawa et al. reported that blood flow decreased by 
45–50% of baseline at reperfusion, while pLc was able to reduce 
the  damage  to  30–35%  of  baseline.  However,  the  blood  flow 
preservation, measured by the laser Doppler technique, was not 
accompanied by functional recovery of hepatocytes (Yonezawa 
et al., 2005). The laser Doppler recordings are influenced by probe 
dimension, because the signal is produced by red blood cell motion 
in all vessels in the scanned tissue. Therefore, laser Doppler signal 
does not reveal changes in flow distribution in the microvessels, 
because of summation in blood flow of hepatic arterioles, sinu-
soids, and portal venules. Previous data indicate that 30 min of 
hepatic ischemia and 60 min of reperfusion are able to reduce by 
10–15% sinusoidal blood flow, when monitoring hepatic lobules by 
intravital microscopy, measuring obstruction of individual capil-
lary in the liver (Eipel et al., 2004). These differences may be due to 
the measurement methods. Our data, in a different experimental 
model, indicate that pLc is very powerful in its ability to preserve 
the microvascular network from I/R injury.
The increase in capillary blood flow may be due to the vascu-
lar resistance reduction related to the release of NO and EDHF 
and subsequent changes in vascular smooth muscle cells, as previ-
ously reported (Pola et al., 1991; Signorelli et al., 2001). However, 
the increase in capillary perfusion may also be due to the leak-
age reduction and consequent accumulation of extravascular fluid 
able to compress vascular networks and reduce blood flow velocity. 
Therefore, during I/R injury pLc shows protective effects on micro-
vascular networks promoting an adequate blood supply to tissues 
through the release of two different molecules derived from vascular 
endothelial cells. Our results indicate that NO together with EDHF 
mediate vasodilatation, while EDHF release primarily acts to prevent 
the permeability increase and the leukocyte adhesion (Figure 8).
In conclusion, the present data indicate that the scavenger activ-
ity of pLc is very important in opposing deleterious action of ROS 
and thus protects the vascular endothelium from leukocyte adhe-
sion and leakage. To the end we can consider these effects maintain 
the capillary viability and perfusion. The protection exerted by 
pLc emphasizes the potential therapeutic use of antioxidants in 
ischemic and post-ischemic vascular disorders.
FiGuRE 8 | Scheme of mechanisms triggered by pLc during  
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